secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001493152-24-020446
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics receives Nasdaq delisting notice for failing minimum equity requirement again
--------------------------------------------------------------------------------

- On May 16, 2024, Nasdaq notified Vivos that stockholders' equity fell below $2.5M as of March 31, 2024.
- Company previously regained compliance on May 6, 2024, but new Q1 10-Q filing shows equity < $2.5M.
- Company has filed appeal; delisting is stayed pending Hearing Panel decision.
- If delisted, material adverse effect on stock price, liquidity, capital raising, and reputation.
- No assurance the company can regain or maintain compliance with the minimum equity requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224020446/0001493152-24-020446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224020446/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer